Envestnet Asset Management
RCKT icon

Envestnet Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Envestnet Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,286
Closed -$229K – 4534
2025
Q1 		$229K Buy
34,286
+1,864
+6% +$18.4K ﹤0.01% 4077
2024
Q4 		$408K Buy
32,422
+1,280
+4% +$19.3K ﹤0.01% 3703
2024
Q3 		$575K Buy
31,142
+1,351
+5% +$27.7K ﹤0.01% 3469
2024
Q2 		$641K Buy
29,791
+1,222
+4% +$28.1K ﹤0.01% 3313
2024
Q1 		$770K Sell
28,569
-2,182
-7% -$62K ﹤0.01% 3193
2023
Q4 		$922K Buy
30,751
+5,992
+24% +$132K ﹤0.01% 2990
2023
Q3 		$507K Buy
24,759
+7,315
+42% +$133K ﹤0.01% 3247
2023
Q2 		$347K Buy
17,444
+3,356
+24% +$67.8K ﹤0.01% 3414
2023
Q1 		$241K Buy
14,088
+1,048
+8% +$20.5K ﹤0.01% 3558
2022
Q4 		$255K Buy
+13,040
New +$240K ﹤0.01% 3536

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Envestnet Asset Management's RCKT Position: Q2 2025 in Review

Envestnet Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 34,286 shares — an estimated $229K sold.

Envestnet Asset Management first reported a position in RCKT in Q4 2022 and held it in 10 quarters. The position peaked at $922K in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Envestnet Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 34,286 Rocket Pharmaceuticals shares in Q2 2025, an estimated $229K.
  • Envestnet Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Envestnet Asset Management's Rocket Pharmaceuticals position peaked at $922K in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.